PT  - JOURNAL ARTICLE
AU  - Tjan, Lidya Handayani
AU  - Furukawa, Koichi
AU  - Kurahashi, Yukiya
AU  - Sutandhio, Silvia
AU  - Nishimura, Mitsuhiro
AU  - Arii, Jun
AU  - Mori, Yasuko
TI  - High neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination
AID  - 10.1101/2022.04.19.22273940
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.19.22273940
4099  - http://medrxiv.org/content/early/2022/04/20/2022.04.19.22273940.short
4100  - http://medrxiv.org/content/early/2022/04/20/2022.04.19.22273940.full
AB  - The VOC of SARS-CoV-2, Omicron (BA.1, BA.1.1, BA.2, or BA.3), is associated with an increased risk of reinfection. BA.2 has become the next dominant variant worldwide. Although BA.2 infection has been shown to be mild illness, its high transmissibility will result in high numbers of cases. In response to the surge of Omicron BA.1 cases, booster vaccination was initiated in many countries. But there is limited evidence regarding the effectiveness of a booster vaccination against BA.2. We collected blood samples from 84 physicians at Kobe University Hospital, Japan, in January 2022 ∼7 months after they had received two BNT162b2 vaccinations and ∼2 weeks after their booster vaccination. We performed a serum neutralizing assay against BA.2 using authentic virus.Although most of the participants had no or a very low titer of neutralizing antibody against BA.2 at 7 months after two BNT162b2 vaccinations, the titer increased significantly at 2 weeks after the booster vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHyogo prefectural governmentAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the ethical committee of the Kobe University Graduate School of Medicine (approval code: B200200).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.